Inflammatory bowel disease (IBD) has a peak age of diagnosis before the age of 35 years.
Concerns about infertility, adverse pregnancy outcomes, and heritability of IBD have …

2. Methods This document represents the third version of the European Consensus on
reproduction in IBD. The development of this Consensus included the formulation of …

The management of inflammatory bowel disease requires continuous medical therapy to
achieve and maintain disease control. Thus, women can be exposed to different drugs …

Abstract Background and Aims Evidence on the safety of newer biologics during pregnancy
is limited. We aimed to assess the safety of ustekinumab and vedolizumab treatment during …

Background Evidence on ustekinumab safety in pregnancy is gradually expanding, but its
clearance in the postnatal period is unknown. The aim of this study was to investigate …

Background Ustekinumab, a human immunoglobulin G1 monoclonal antibody that binds to
and inhibits interleukin (IL)‐12/IL‐23, is indicated for multiple immune‐mediated diseases …

Background & Aims Vedolizumab and ustekinumab pharmacokinetics in pregnancy and the
infant after in utero exposure remain incompletely defined. We aim to define the antenatal …

Objective Because pregnancy outcomes tend to be worse in women with inflammatory
bowel disease (IBD) than in those without, we aimed to update consensus statements that …

Background Biological agents cross the placenta, resulting in detectable blood levels in the
neonate. Neonatal vaccinations are essential to prevent serious infections. Aim To review …

Background: Pregnancy outcomes in patients with inflammatory bowel disease with
quiescent disease are similar to those in the general population. Data from the Pregnancy …